Overview

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

Status:
Completed
Trial end date:
2018-12-06
Target enrollment:
Participant gender:
Summary
The study is intended to provide additional post-marketing safety data regarding the use of etoricoxib for the indication of ankylosing spondylitis.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Cyclooxygenase 2 Inhibitors
Etoricoxib